Literature DB >> 19351799

An investigation of the subacute effects of ecstasy on neuropsychological performance, sleep and mood in regular ecstasy users.

A Pirona1, M J Morgan.   

Abstract

The aim of this study was to differentiate the subacute from the chronic effects of ecstasy. Regular ecstasy users who subsequently chose to take ecstasy (experimental group: E, N = 16) were compared with regular ecstasy users who opted not to (control group: C, N = 16). Groups were assessed with neuropsychological and psychometric measures at drug-free baseline before ecstasy use and 1 and 4 days after use. Ecstasy users who consumed ecstasy (E) did not differ from those who did not (C) in relation to age, estimated IQ, personality or past substance use, including ecstasy. At baseline, E reported being more energetic, lively and cheerful whereas the day after ecstasy use they reported being more muddled, afraid, sad and dejected than C. However, this was not significant after controlling for sleep deprivation. Mood returned to baseline within 3 days and there were no group differences in Beck depression inventory scores at any of the three testing sessions. There were no subacute effects of ecstasy on working memory, story recall, impulsivity, or decision-making. However, at baseline and the day after use ecstasy users made poorer decisions, and were less sensitive to punishment, in the Somatic marker sensitivity test. These findings suggest that previous reports of marked subacute effects of ecstasy use may have been confounded by chronic polydrug use before use, co-substance use and sleep disturbances after use.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19351799     DOI: 10.1177/0269881109102780

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  8 in total

1.  Residual neurocognitive features of long-term ecstasy users with minimal exposure to other drugs.

Authors:  John H Halpern; Andrea R Sherwood; James I Hudson; Staci Gruber; David Kozin; Harrison G Pope
Journal:  Addiction       Date:  2011-02-15       Impact factor: 6.526

2.  The acute effects of 3,4-methylenedioxymethamphetamine and d-methamphetamine on human cognitive functioning.

Authors:  Con Stough; Rebecca King; Katherine Papafotiou; Phillip Swann; Edward Ogden; Keith Wesnes; Luke A Downey
Journal:  Psychopharmacology (Berl)       Date:  2011-10-22       Impact factor: 4.530

Review 3.  The ugly side of amphetamines: short- and long-term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'), methamphetamine and D-amphetamine.

Authors:  Thomas Steinkellner; Michael Freissmuth; Harald H Sitte; Therese Montgomery
Journal:  Biol Chem       Date:  2011-01       Impact factor: 3.915

4.  Procedural and declarative memory task performance, and the memory consolidation function of sleep, in recent and abstinent ecstasy/MDMA users.

Authors:  Mark Blagrove; Jennifer Seddon; Sophie George; Andrew C Parrott; Robert Stickgold; Matthew P Walker; Katy A Jones; Michael J Morgan
Journal:  J Psychopharmacol       Date:  2010-07-08       Impact factor: 4.153

Review 5.  The 21st century psychedelic renaissance: heroic steps forward on the back of an elephant.

Authors:  Ben Sessa
Journal:  Psychopharmacology (Berl)       Date:  2017-08-23       Impact factor: 4.415

Review 6.  Why Psychiatry Needs 3,4-Methylenedioxymethamphetamine: A Child Psychiatrist's Perspective.

Authors:  Ben Sessa
Journal:  Neurotherapeutics       Date:  2017-07       Impact factor: 7.620

7.  An observational study on the sub-acute effects of mephedrone on mood, cognition, sleep and physical problems in regular mephedrone users.

Authors:  Lina Homman; Jessica Seglert; Michael J Morgan
Journal:  Psychopharmacology (Berl)       Date:  2018-06-26       Impact factor: 4.530

Review 8.  The Role of Working Memory for Cognitive Control in Anorexia Nervosa versus Substance Use Disorder.

Authors:  Samantha J Brooks; Sabina G Funk; Susanne Y Young; Helgi B Schiöth
Journal:  Front Psychol       Date:  2017-09-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.